Nikko Asset Management Americas, Inc. - IOVANCE BIOTHERAPEUTICS INC ownership

IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 253 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.45 and the average weighting 0.3%.

Quarter-by-quarter ownership
Nikko Asset Management Americas, Inc. ownership history of IOVANCE BIOTHERAPEUTICS INC
ValueSharesWeighting
Q2 2023$17,508,918
+13.3%
2,490,600
-2.3%
0.18%
+3.4%
Q1 2023$15,446,885
-6.4%
2,548,991
-1.5%
0.18%
-25.2%
Q4 2022$16,509,003
-34.6%
2,587,618
-4.1%
0.24%
-26.1%
Q3 2022$25,240,000
-15.0%
2,699,413
-3.6%
0.32%
-12.3%
Q2 2022$29,704,000
-24.3%
2,799,642
+17.7%
0.37%
+27.4%
Q1 2022$39,243,000
-52.5%
2,378,336
-52.1%
0.29%
-33.6%
Q4 2021$82,619,000
-43.0%
4,965,096
-22.2%
0.43%
-30.3%
Q3 2021$144,972,000
-27.0%
6,380,803
-17.4%
0.62%
-19.8%
Q2 2021$198,527,000
+17.3%
7,724,788
+44.5%
0.78%
-6.3%
Q1 2021$169,250,000
-17.5%
5,345,861
+20.8%
0.83%
-28.9%
Q4 2020$205,269,000
+76.7%
4,423,910
+25.7%
1.17%
+13.3%
Q3 2020$116,152,000
+54.1%
3,519,745
+27.8%
1.03%
+4.3%
Q2 2020$75,365,000
+12.3%
2,754,568
+22.9%
0.99%
+56.9%
Q1 2020$67,086,000
+82.7%
2,241,044
+68.9%
0.63%
+8.8%
Q4 2019$36,718,000
+48.7%
1,326,509
-2.2%
0.58%
+31.7%
Q3 2019$24,685,000
-20.4%
1,356,302
+7.3%
0.44%
-27.8%
Q2 2019$30,996,000
+603.8%
1,264,096
+173.0%
0.61%
+424.1%
Q1 2019$4,404,000463,0700.12%
Other shareholders
IOVANCE BIOTHERAPEUTICS INC shareholders Q3 2020
NameSharesValueWeighting ↓
ACUTA CAPITAL PARTNERS, LLC 2,222,701$25,005,0008.92%
Broadfin Capital, LLC 4,894,361$55,062,0008.10%
GREAT POINT PARTNERS LLC 3,496,340$39,334,0006.13%
FRAZIER MANAGEMENT LLC 2,188,331$24,619,0004.51%
Prosight Management, LP 715,317$8,047,0004.49%
Avoro Capital Advisors LLC 8,662,720$97,456,0004.48%
QVT Financial LP 821,361$8,748,0002.26%
Perceptive Advisors 7,290,199$82,014,0002.19%
Rhenman & Partners Asset Management AB 1,290,495$14,518,0001.46%
EMORY UNIVERSITY 185,915$2,092,0001.37%
View complete list of IOVANCE BIOTHERAPEUTICS INC shareholders